Literature DB >> 34407676

Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.

Grace Champlin1, Scott N Hwang2, Andrew Heitzer3, Juan Ding4, Lisa Jacola3, Jeremie H Estepp5,6, Winfred Wang5, Kenneth I Ataga7,8, Curtis L Owens8, Justin Newman9, Allison A King10, Robert Davis11, Guolian Kang4, Jane S Hankins5.   

Abstract

Silent cerebral infarcts and arteriopathy are common and progressive in individuals with sickle cell anemia. However, most data describing brain lesions in sickle cell anemia are cross-sectional or derive from pediatric cohorts with short follow-up. We investigated the progression of silent cerebral infarct and cerebral vessel stenosis on brain MRI and MRA, respectively, by describing the incidence of new or worsening lesions over a period of up to 25 years among young adults with sickle cell anemia and explored risk factors for progression. Forty-four adults with sickle cell anemia (HbSS or HbSβ0thalassemia), exposed to chronic transfusions (n = 12) or hydroxyurea (n = 32), median age 19.2 years (range 18.0-31.5), received a screening brain MRI/MRA and their results were compared with a clinical exam performed during childhood and adolescence. We used exact log-rank test to compare MRI and MRA progression among any two groups. The hazard ratio (HR) and 95% confidence interval (CI) were calculated from Cox regression analyses. Progression of MRI and MRA occurred in 12 (27%) and 4 (9%) young adults, respectively, relative to their pediatric exams. MRI progression risk was high among participants with abnormal pediatric exams (HR: 11.6, 95% CI: 2.5-54.7) and conditional or abnormal transcranial Doppler ultrasound velocities (HR: 3.9, 95% CI: 1.0-15.1). Among individuals treated with hydroxyurea, high fetal hemoglobin measured in childhood was associated with lower hazard of MRI progression (HR: 0.86, 95% CI: 0.76-0.98). MRA progression occurred more frequently among those with prior stroke (HR: 8.6, 95% CI: 1.2-64), abnormal pediatric exam (P = 0.00084), and elevated transcranial Doppler ultrasound velocities (P = 0.004). Brain MRI/MRA imaging in pediatrics can identify high-risk patients for CNS disease progression in young adulthood, prompting consideration for early aggressive treatments.

Entities:  

Keywords:  Stroke; disease-modifying therapy; sickle cell anemia; silent cerebral infarct; vasculopathy; young adult

Mesh:

Substances:

Year:  2021        PMID: 34407676      PMCID: PMC8649936          DOI: 10.1177/15353702211035778

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  29 in total

1.  Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).

Authors:  Russell E Ware; Ronald W Helms
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  Silent cerebral infarcts and cerebral aneurysms are prevalent in adults with sickle cell anemia.

Authors:  Adetola A Kassim; Sumit Pruthi; Matthew Day; Mark Rodeghier; Melissa C Gindville; Max A Brodsky; Michael R DeBaun; Lori C Jordan
Journal:  Blood       Date:  2016-03-03       Impact factor: 22.113

Review 3.  Transition and sickle cell disease.

Authors:  Michael R DeBaun; Joseph Telfair
Journal:  Pediatrics       Date:  2012-10-01       Impact factor: 7.124

4.  Chronic and acute anemia and extracranial internal carotid stenosis are risk factors for silent cerebral infarcts in sickle cell anemia.

Authors:  Françoise Bernaudin; Suzanne Verlhac; Cécile Arnaud; Annie Kamdem; Manuela Vasile; Florence Kasbi; Isabelle Hau; Fouad Madhi; Christine Fourmaux; Sandra Biscardi; Ralph Epaud; Corinne Pondarré
Journal:  Blood       Date:  2014-12-22       Impact factor: 22.113

Review 5.  TCD in sickle cell disease: an important and useful test.

Authors:  Robert J Adams
Journal:  Pediatr Radiol       Date:  2005-02-10

6.  Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure.

Authors:  Michael R DeBaun; Sharada A Sarnaik; Mark J Rodeghier; Caterina P Minniti; Thomas H Howard; Rathi V Iyer; Baba Inusa; Paul T Telfer; Melanie Kirby-Allen; Charles T Quinn; Françoise Bernaudin; Gladstone Airewele; Gerald M Woods; Julie Ann Panepinto; Beng Fuh; Janet K Kwiatkowski; Allison A King; Melissa M Rhodes; Alexis A Thompson; Mark E Heiny; Rupa C Redding-Lallinger; Fenella J Kirkham; Hernan Sabio; Corina E Gonzalez; Suzanne L Saccente; Karen A Kalinyak; John J Strouse; Jason M Fixler; Mae O Gordon; J Phillip Miller; Michael J Noetzel; Rebecca N Ichord; James F Casella
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

7.  Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.

Authors:  Kathleen J Helton; Robert J Adams; Karen L Kesler; Alex Lockhart; Banu Aygun; Catherine Driscoll; Matthew M Heeney; Sherron M Jackson; Lakshmanan Krishnamurti; Scott T Miller; Sharada A Sarnaik; William H Schultz; Russell E Ware
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia.

Authors:  Mathula Thangarajh; Genyan Yang; Dana Fuchs; Maria R Ponisio; Robert C McKinstry; Alok Jaju; Michael J Noetzel; James F Casella; Emily Barron-Casella; W Craig Hooper; Sheree L Boulet; Christopher J Bean; Meredith E Pyle; Amanda B Payne; Jennifer Driggers; Heidi A Trau; Bruce A Vendt; Mark Rodeghier; Michael R DeBaun
Journal:  Br J Haematol       Date:  2012-09-07       Impact factor: 6.998

Review 9.  Stroke in patients with sickle cell disease.

Authors:  Jennifer Webb; Janet L Kwiatkowski
Journal:  Expert Rev Hematol       Date:  2013-06       Impact factor: 2.929

10.  Cerebral Infarcts and Vasculopathy in Tanzanian Children With Sickle Cell Anemia.

Authors:  Mboka Jacob; Dawn E Saunders; Raphael Z Sangeda; Magda Ahmed; Hilda Tutuba; Frank Kussaga; Balowa Musa; Bruno Mmbando; April E Slee; Jamie M Kawadler; Julie Makani; Fenella J Kirkham
Journal:  Pediatr Neurol       Date:  2019-12-27       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.